Cardiac morbidity in advanced chronic myelogenous leukaemia patients treated by successive allogeneic stem cell transplantation with busulphan/cyclophosphamide conditioning after imatinib mesylate administration

British Journal of Haematology

Volumn 121, Issue 3, 2003, Pages 469-472

  Sohn, Sang Kyun ^a   Gwang Kim, Jong ^a   Hwan Kim, Dong ^a   Bo Lee, Kyu ^a  

^a Kyungpook National University Hospital   (South Korea)

Author keywords

Allogeneic; Chronic myelogenous leukaemia; Imatinib mesylate

Indexed keywords

ACICLOVIR; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIVIRUS AGENT; BUSULFAN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FLUCONAZOLE; IMATINIB; METHOTREXATE; NORFLOXACIN;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CARDIOMEGALY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CASE REPORT; CHRONIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; DYSPNEA; EDEMA; GRAFT VERSUS HOST REACTION; HUMAN; MALE; OPPORTUNISTIC INFECTION; PERICARDIAL EFFUSION; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; SPLENOMEGALY; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC AGENTS; BUSULFAN; CARDIOMEGALY; CYCLOPHOSPHAMIDE; ECHOCARDIOGRAPHY, DOPPLER; ELECTROCARDIOGRAPHY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKEMIA, MYELOID, CHRONIC; LUNG; MALE; PIPERAZINES; PYRIMIDINES; REOPERATION; STEM CELL TRANSPLANTATION; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 0037677922     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2003.04288.x     Document Type: Article

References (12)

1. Burton, C., Azzi, A. & Kerridge, I. (2002) Adverse events after imatinib mesylate therapy. New England Journal of Medicine, 346, 712-713.
2. Deininger, M.W.N., Schleuning, M., Olavarria, E., Fischer, T., Nagler, A., Sayer, H., Boque, C., Volin, L., Piotelli, G., Russel, N., Wandt, H., Schanz, U., Greinix, H., Sponk, L., Verdonck, L., Lennard, A., Wimmer, M., Hegenbart, U., Lange, T. & Niederwieser, D. for the Chronic Leukemia Working Party of the EBMT (2002) Safety and efficacy of glivec prior to allografting for CML and Ph-positive ALL: European experience. Bone Marrow Transplantation, 29, s31.
3. Druker, B.J., Sawyers, C.L., Kantarjian, H., Resta, D.J., Reese, S.F., Ford, J.M., Capdeville, R. & Talpaz, M. (2001a) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. New England Journal of Medicine, 344, 1038-1042.
4. Druker, B.J., Talpaz, M., Resta, D.J., Peng, B., Buchdunger, E., Ford, J.M., Lydon, N.B., Kantarjian, H., Capdeville, R., Ohno-Jones, S. & Sawyers, C.L. (2001b) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. New England Journal of Medicine, 344, 1031-1037.
5. Druker, B.J., Sawyers, C.L., Capdeville, R., Ford, J.M., Baccarani, M. & Goldman, J.M. (2001c) Chronic myelogenous leukemia. Hematology (American Society of Hematology Education Program), pp 87-112. American Society of Hematology, Washington.
6. Fischer, T., Reifenrath, C., Hess, G.R., Corsetti, M.T., Kreil, S., Beck, J., Meinhardt, P., Beltrami, G., Schuch, B., Gschaidmeier, H., Hehlmann, R., Hochhaus, A., Carella, A. & Huber, C. (2002) Safety and efficacy of STI-571 (imatinib mesylate) in patients with bcr/abl-positive chronic myelogenous leukemia (CML) after autologous peripheral blood stem cell transplantation (PBSCT). Leukemia, 6, 1220-1228.
7. Kantarjian, H.M., O'Brien, S., Cortes, J.E., Giralt, S.A., Rios, M.B., Shan, J., Giles, F.J., Thomas, D.A., Faderl, S., De Lima, M., Garcia-Manero, G., Champlin, R., Arlinghaus, R. & Talpaz, M. (2002) Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood, 100, 1590-1595.
8. Nevill, T.J., Barnett, M.J., Klingemann, H.G., Reece, D.E., Shepherd, J.D. & Phillips, G.L. (1991) Regimen-related toxicity of a busulfan - cyclophosphamide conditioning regimen in 70 patients undergoing allogeneic bone marrow transplantation. Journal of Clinical Oncology, 9, 1224-1232.
9. Ohyashiki, K., Kuriyama. Y., Nakajima, A., Tauchi, T., Ito, Y., Miyazawa, H., Kimura, Y., Serizawa, H. & Ebihara, Y. (2002) Imatinib mesylate-induced hepato-toxicity in chronic myeloid leukemia demonstrated focal necrosis resembling acute viral hepatitis. Leukemia, 16, 2160-2161.
10. Rosenthal, M.A., Grigg, A.P. & Sheridan, W.P. (1994) High dose busulphan/cyclophosphamide for autologous bone marrow transplantation is associated with minimal non-hemopoietic toxicity. Leukemia and Lymphoma, 14, 279-283.
11. Sawyers, C.L., Hochhaus, A., Feldman, E., Goldman, J.M., Miller, C.B., Ottmann, O.G., Schiffer, C.A., Talpaz, M., Guilhot, F., Deininger, M.W., Fischer, T., O'Brien, S.G., Stone, R.M., Gambacorti-Passerini, C.B., Russell, N.H., Reiffers, J.J., Shea, T.C., Chapuis, B., Coutre, S., Tura, S., Morra, E., Larson, R.A., Saven, A., Peschel, C., Gratwohl, A., Mandelli F., Ben-Am, M., Gathmann, I., Capdeville, R., Paquette, R.L. & Druker, B.J. (2002) Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood, 99, 3530-3539.
12. Spencer, A., O'Brien, S.G. & Goldman. J.M. (1995) Options for therapy in chronic myeloid leukaemia. British Journal of Haematology, 91, 2-7.